12,400 Shares in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Acquired by Versor Investments LP

Versor Investments LP purchased a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,400 shares of the company’s stock, valued at approximately $101,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PHAT. Jennison Associates LLC raised its stake in shares of Phathom Pharmaceuticals by 20.4% in the 4th quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock valued at $57,348,000 after acquiring an additional 1,196,118 shares during the period. Portolan Capital Management LLC increased its holdings in Phathom Pharmaceuticals by 50.4% in the 3rd quarter. Portolan Capital Management LLC now owns 1,699,918 shares of the company’s stock valued at $30,735,000 after purchasing an additional 569,829 shares in the last quarter. Checkpoint Capital L.P. raised its position in Phathom Pharmaceuticals by 71.9% in the third quarter. Checkpoint Capital L.P. now owns 1,504,307 shares of the company’s stock valued at $27,198,000 after purchasing an additional 629,307 shares during the period. FMR LLC lifted its stake in shares of Phathom Pharmaceuticals by 49,000.7% during the third quarter. FMR LLC now owns 1,304,114 shares of the company’s stock worth $23,578,000 after purchasing an additional 1,301,458 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Phathom Pharmaceuticals by 17.5% during the third quarter. State Street Corp now owns 922,788 shares of the company’s stock worth $16,684,000 after purchasing an additional 137,539 shares in the last quarter. 99.01% of the stock is owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Stock Performance

NASDAQ:PHAT opened at $5.58 on Wednesday. The stock has a market cap of $381.54 million, a price-to-earnings ratio of -0.98 and a beta of 0.54. Phathom Pharmaceuticals, Inc. has a one year low of $5.07 and a one year high of $19.71. The business’s 50-day simple moving average is $6.48 and its 200 day simple moving average is $11.37.

Insiders Place Their Bets

In related news, Director Frank Karbe acquired 12,500 shares of Phathom Pharmaceuticals stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of $7.93 per share, for a total transaction of $99,125.00. Following the purchase, the director now directly owns 57,000 shares of the company’s stock, valued at $452,010. The trade was a 28.09 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 19,109 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $125,928.31. Following the transaction, the insider now directly owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. This represents a 5.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,987 shares of company stock worth $240,551 in the last three months. 24.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Phathom Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $23.00.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.